플루메타손

용도

• Labeled indications (acute and chronic dermatoses)
• Labeled indications (acute and chronic dermatoses)
• General anti-inflammatory/immunosuppressive
• Labeled indications (musculoskeletal conditions, allergic states)
• General anti-inflammatory
• Labeled indications (musculoskeletal conditions, dermatoses, allergic states, shock)
• Labeled indications
• Labeled indications (joint inflammation)
• Labeled indications (localized lesions)
• General anti-inflammatory/immunosuppressive

투여 방법

가능한 부작용

• Polydipsia (PD), polyuria (PU), and polyphagia (PP)
• Weight gain and lipidemias
• Dull, dry haircoat and dermatological thinning
• Panting
• Gastrointestinal effects: vomiting, diarrhea, GI ulceration
• Hepatopathy: elevated liver enzymes (ALP, ALT)
• Pancreatitis
• Endocrine: activation or worsening of diabetes mellitus, iatrogenic hyperadrenocorticism (Cushingoid effects) with sustained use
• Musculoskeletal: muscle wasting, retarded growth in young animals
• Behavioral changes: depression, lethargy, viciousness
• Immunosuppression: increased susceptibility to infections

주의사항 및 금기

• Last trimester of pregnancy (may induce parturition)
• Systemic fungal infections (unless used for Addison's replacement therapy)
• Idiopathic thrombocytopenia (specifically contraindicated for IM administration)
• Known hypersensitivity to the compound
• Chronic corticosteroid therapy of systemic diseases using sustained-release injectable forms
• **Tapering Required**: Animals that have received systemic glucocorticoids (other than short 'burst' therapy) must be tapered off slowly to allow endogenous ACTH and corticosteroid function to recover. **Stress Dosing**: If an animal undergoes a 'stressor' (e.g., surgery, trauma, illness) during the tapering process or before normal adrenal/pituitary function resumes, additional glucocorticoids should be administered. **Pregnancy Warning**: Corticosteroid therapy may induce parturition in large animal species during the latter stages of pregnancy. Categorized as Class C for canine and feline pregnancy (use cautiously as a last resort when benefits clearly outweigh risks).

약물 상호작용

• Amphotericin B: Administered concomitantly with glucocorticoids may cause hypokalemia
• Anticholinesterase agents (e.g., pyridostigmine, neostigmine): In patients with myasthenia gravis, concomitant administration may lead to profound muscle weakness. Discontinue anticholinesterase at least 24 hours prior if possible.
• Aspirin: Glucocorticoids may reduce salicylate blood levels
• Barbiturates: May increase the metabolism of glucocorticoids and decrease flumethasone blood levels
• Cyclophosphamide: Glucocorticoids may inhibit the hepatic metabolism of cyclophosphamide; dosage adjustments may be required
• Cyclosporine: Concomitant administration may increase the blood levels of each by mutually inhibiting hepatic metabolism
• Diazepam: Flumethasone may decrease diazepam levels
• Diuretics, potassium-depleting (e.g., spironolactone, triamterene): Administered concomitantly with glucocorticoids may cause hypokalemia
• Ephedrine: May reduce flumethasone blood levels
• Insulin: Insulin requirements may increase in patients receiving glucocorticoids

자주 묻는 질문